Diabetes Technology and Therapy in the Pediatric Age Group

Niedzwiecki P , Pilacinski S , Uruska A , et al. Influence of remission and its duration on development of early microvascular complications in young adults with type 1 diabetes. J Diabetes Complications, 2015; 29: 1105–1111.

Palmer JP , Fleming GA , Greenbaum CJ , et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta cell function: report of an ADA workshop, 21–22 October 2001. Diabetes, 2004; 53: 250–264.

Kahkoska AR , Adair LA , Aiello AE , et al. Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. Pediatr Diabetes, 2019; 20: 556–566.

Battaglia M , Ahmed S , Anderson MS , et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care, 2020; 43: 5–12.

Champakanath A , Akturk HK , Alonso GT , et al. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care, 2022; 45: 750–753.

Prahalad P , Ding VY , Zaharieva DP , et al. Teamwork, targets, technology, and tight control in newly diagnosed type 1 diabetes: the Pilot 4T Study. J Clin Endocrinol Metab, 2022; 107: 998–1008.

Ebekozien O , Mungmode A , Odugbesan O , et al. Addressing type 1 diabetes health inequities in the United States: approaches from the T1D Exchange QI Collaborative. J Diabetes, 2022; 14: 79–82.

Hill-Briggs F , Adler NE , Berkowitz SA , et al. Social determinants of health and diabetes: a scientific review. Diabetes Care, 2020; 44: 258–279.

Lipman TH , Hawkes CP . Racial and socioeconomic disparities in pediatric type 1 diabetes: time for a paradigm shift in approach. Diabetes Care, 2021; 44: 14–16.

Cardona-Hernandez R , Schwandt A , Alkandari H , et al.; for the SWEET study group. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the International Pediatric Registry SWEET. Diabetes Care, 2021; 44: 1176–1184.

Johnson SR , Holmes-Walker DJ , Chee M , et al. Universal subsidized continuous glucose monitoring funding for young people with type 1 diabetes: uptake and outcomes over 2 years, a population-based study. Diabetes Care, 2022; 45: 391–397.

Messaaoui A , Tenoutasse S , Crenier L. Flash glucose monitoring accepted in daily life of children and adolescents with type 1 diabetes and reduction of severe hypoglycemia in real-life use. Diabetes Technol Ther, 2019; 21: 329–335.

Swaney EE , McCombe J , Coggan B , et al. Has subsidized continuous glucose monitoring improved outcomes in pediatric diabetes? Pediatr Diabetes, 2020; 21: 1292–1300.

Tauschmann M , Hermann JM , Freiberg C , et al. Reduction in diabetic ketoacidosis and severe hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3,553 subjects from the DPV registry. Diabetes Care, 2020; 43: e40–42.

Catherine JP , Russell MV , Peter CH . The impact of race and socioeconomic factors on paediatric diabetes. EClinicalMedicine, 2021; 42: 101186.

Pauley ME , Berget C , Messer LH , et al. Barriers to uptake of insulin technologies and novel solutions. Med Devices (Auckl), 2021; 14: 339–354.

Piccini B , Pessina B , Casalini E , et al. Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes. Pediatr Diabetes, 2022; 23: 1647–1655.

Arrieta A , Battelino T , Scaramuzza AE , et al. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab, 2022; 24: 1370–1379.

Kesavadev J , Basanth A , Krishnan G , et al. Real-world user and clinician perspective and experience with MiniMed 780G advanced hybrid closed loop system. Diabetes Ther, 2023; 14: 1319–1330.

Šoupal J , Škrha J , Fajmon M , et al. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther, 2014; 16: 198–203.

Boughton CK. Fully closed-loop insulin delivery—are we nearly there yet? Lancet Digit Health, 2021; 3: e689–e690.

Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 2019; 42: 1593–1603.

Sawyer A , Sobczak M , Forlenza GP , et al. Glycemic control in relation to technology use in a single-center cohort of children with type 1 diabetes. Diabetes Technol Ther, 2022; 24: 409–415.

Agarwal S , Schechter C , Gonzalez J , et al. Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther, 2021; 23: 306–313.

Brown SA , Kovatchev BP , Raghinaru D , et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381: 1707–1717.

Breton MD , Kanapka LG , Beck RW , et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383: 836–845.

Wadwa RP , Reed ZW , Buckingham BA , et al. Trial of hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med, 2023; 388: 991–1001.

Peacock S , Frizelle I , Hussain S. A systematic review of commercial hybrid closed-loop automated insulin delivery systems. Diabetes Ther, 2023; 14: 839– 855.

ElSayed NA , Aleppo G , Aroda VR , et al. 7. Diabetes Technology: standards of care in diabetes—2023. Diabetes Care, 2023; 46 (Suppl 1): S111–S127.

ElSayed NA , Aleppo G , Aroda VR , et al. 14. Children and adolescents: standards of care in diabetes—2023. Diabetes Care, 2023; 46 (Suppl 1): S230–S253.

Sherr JL , Schoelwer M , Dos Santos TJ , et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: insulin delivery. Pediatr Diabetes, 2022; 23: 1406–1431.

Braune K , Hussain S , Lal R. The first regulatory clearance of an open-source automated insulin delivery algorithm. J Diabetes Sci Technol, 2023; 17: 1139–1141.

Bergenstal RM , Garg S , Weinzimer SA , et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316: 1407–1408.

Forlenza GP , Ekhlaspour L , Breton M , et al. Successful at-home use of the Tandem Control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther, 2019; 21: 159–169.

Franceschi R , Mozzillo E , Di Candia F , et al. A systematic review on the impact of commercially available hybrid closed loop systems on psychological outcomes in youths with type 1 diabetes and their parents. Diabet Med, 2023; 40: e15099.

Commissariat PV , Roethke LC , Finnegan JL , et al. Youth and parent preferences for an ideal AP system: it is all about reducing burden. Pediatr Diabetes, 2021; 22: 1063–1070.

Miller KM , Beck RW , Foster NC , et al. HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D Exchange clinic registry findings. Diabetes Technol Ther, 2020; 22: 645–650.

Akturk HK , Agarwal S , Hoffecker L , et al. Inequity in racial-ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards. Diabetes Care, 2021; 44: e121–e123.

Addala A , Hanes S , Naranjo D , et al. Provider implicit bias impacts pediatric type 1 diabetes technology recommendations in the United States: findings from the gatekeeper study. J Diabetes Sci Technol, 2021; 15: 1027–1033.

Tauschmann M , Forlenza G , Hood K , et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes, 2022; 23: 1390–1405.

Haskova A , Radovnicka L , Petruzelkova L , et al. Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial. Diabetes Care, 2020; 43: 2744– 2750.

Laffel LM , Kanapka LG , Beck RW , et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA, 2020; 323: 2388–2396.

DeSalvo DJ , Miller KM , Hermann JM , et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes, 2018; 19: 1271–1275.

Addala A , Auzanneau M , Miller K , et al. A Decade of disparities in diabetes technology use and HbA(1c) in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care, 2021; 44: 133–140.

Steffes MW , Sibley S , Jackson M , et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care, 2003; 26: 832–836.

Bonfanti R , Bazzigaluppi E , Calori G , et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus. Diabet Med, 1998; 15: 844–850.

Jacobsen LM , Bundy BN , Greco MN , et al. Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol Ther, 2020; 22: 948–953.

Narendran P , Tomlinson C , Beese S , et al. A systematic review and meta-analysis of interventions to preserve insulin-secreting β-cell function in people newly diagnosed with type 1 diabetes: results from intervention studies aimed at improving glucose control. Diabet Med, 2022; 39: e14730.

Chen J , Saxena G , Mungrue IN , et al. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes, 2008; 57: 938–944.

Borowiec AM , Właszczuk A , Olakowska E , et al. TXNIP inhibition in the treatment of diabetes: verapamil as a novel therapeutic modality in diabetic patients. Med Pharm Rep, 2022; 95: 243–250.

Ovalle F , Grimes T , Xu G , et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med, 2018; 24: 1108–1112.